PLANET trial: atorvastatin preferred over rosuvastatin in CKD (with July 2026 correction)
Louis shares a teaching card that atorvastatin is the preferred statin in chronic kidney disease, citing the PLANET trial comparing it with rosuvastatin. His later edit says the original text had a typo: the correct statement is that atorvastatin improved proteinuria but had no effect on eGFR.


